Brevan Howard Capital Management’s NeoGenomics NEO Stock Holding History

Brevan Howard Capital Management’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66,033	Closed	-$490K	–	2415
2026 Q1	$490K	Buy	66,033 +48,458	+276%	+$510K	﹤0.01%	1314
2025 Q4	$207K	Buy	+17,575	New	+$190K	﹤0.01%	1569
2025 Q3	–	Sell	-28,981	Closed	-$212K	–	2174
2025 Q2	$212K	Buy	+28,981	New	+$234K	﹤0.01%	1692

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Brevan Howard Capital Management's NEO Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of NeoGenomics (NEO) in Q2 2026, closing a stake of 66,033 shares — an estimated $490K sold.

Brevan Howard Capital Management first reported a position in NEO in Q2 2025 and held it in 3 quarters. The position peaked at $490K in Q1 2026. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

Brevan Howard Capital Management reported no remaining NeoGenomics position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 66,033 NeoGenomics shares in Q2 2026, an estimated $490K.
Brevan Howard Capital Management first reported a position in NeoGenomics in Q2 2025 and held it in 3 quarters.
Brevan Howard Capital Management's NeoGenomics position peaked at $490K in Q1 2026.
266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.